Results 91 to 100 of about 18,729 (264)
GIP in Cardiovascular and Kidney Disease: From Physiology to Pharmacology
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Aims To provide a comprehensive overview of the cardiovascular and renal effects of glucose‐dependent insulinotropic polypeptide (GIP) by integrating its physiological role with recent human trial data on tirzepatide, the first dual GIP and glucagon‐like peptide‐1 (GLP‐1) receptor agonist.
Michelantonio De Fano +4 more
wiley +1 more source
Frontiers in PharmacologyIntroductionEndothelin-1 (ET-1) regulates renal and vascular function, but the clinical utility of selective ETA receptor antagonists has been limited due to associated fluid retention.
K. Melissa Hallow +5 more
doaj +1 more source
Insulin resistance, kidney outcomes and effects of the endothelin receptor antagonist atrasentan in patients with type 2 diabetes and chronic kidney disease. [PDF]
Cardiovasc Diabetol, 2023 Smeijer JD +9 more
europepmc +1 more source
Hepatology Research, EarlyView.Mineralocorticoid receptor antagonists are known to reduce proteinuria in chronic kidney disease, but their effectiveness in preventing bevacizumab‐related proteinuria has not been well established. In the present multi‐institutional retrospective study, we found that these agents significantly delay the onset of moderate or higher grade proteinuria ...
Tomoki Hori +17 more
wiley +1 more source
International Endodontic Journal, EarlyView.ABSTRACT Background Dental pulp inflammation triggers immune responses involving macrophages and dental pulp stem cells (DPSCs), which interact to regulate angiogenesis essential for tissue repair. M1 pro‐inflammatory macrophages predominate early in pulpitis, and clarifying their angiogenic role is vital in identifying inflammatory regenerative ...
Dineshi Sewvandi Thalakiriyawa +5 more
wiley +1 more source
Current status of bosentan for treatment of pulmonary hypertension
Annals of Cardiac Anaesthesia, 2008 Pulmonary arterial hypertension (PAH) is a debilitating disease associated with significant morbidity and a high mortality if left untreated. Over the past 5 years, there have been significant advances with regard to the understanding of the pathogenesis,
Raja Shahzad, Dreyfus Gilles
doaj
Single-dose pharmacokinetics, safety, and tolerability of the dual endothelin receptor antagonist aprocitentan in subjects with moderate hepatic impairment. [PDF]
Sci Rep, 2022 Fontes MSC +4 more
europepmc +1 more source
International Endodontic Journal, EarlyView.ABSTRACT Aim A growing body of research supports an association between periapical inflammation and an increased risk of various systemic effects. However, there is currently no scientific evidence demonstrating a causal relationship between this inflammation and changes in epithelial or endothelial permeability in patients with apical periodontitis ...
Loredana Bergandi +9 more
wiley +1 more source
Ambrisentan for the treatment of pulmonary arterial hypertension
Drug Design, Development and Therapy, 2008 Brian Casserly1,3, James R Klinger2,31Division of Pulmonary Medicine, The Memorial Hospital of Rhode Island, Pawtucket, RI, USA; 2Division of Pulmonary Sleep and Critical Care Medicine, Rhode Island Hospital; 3Waren Alpert Medical School of Brown ...
Brian Casserly, James R Klinger
doaj